Amubarvimab, previously known as BI 196, represents a noteworthy advancement in antibody development, particularly concerning its ability to inhibit SARS-CoV-2 . This engineered molecule demonstrates https://lewishpjl922585.blog-gold.com/58732443/amubarvimab-a-in-depth-exploration-into-the-antibody-s-promise